Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis affecting the arteries in the lower extremities and is a major cause of morbidity and mortality in developed countries. It is considered a major marker for systemic ischemic events such as stroke and myocardial infarction (MI). Because asymptomatic patients make up a large percentage of the total PAD population, the disease is largely underdiagnosed, under-recognized, and undertreated. However, there is growing recognition that optimal management of PAD requires aggressive secondary prevention measures. Few drugs have been developed specifically for PAD, and the choice of therapies has changed little in recent years, but several novel therapies are in development. Increasing diagnosis and treatment rates, combined with substantial unmet need, make PAD a high-growth opportunity.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 19 country-specific interviews with PAD experts.
Epidemiology: Prevalence of PAD by total population and severity; acute PAD-associated events; diagnosis status.
Population segments in market forecast: Asymptomatic, intermittent claudication, critical limb ischemia.
Emerging therapies: Coverage of select emerging therapies from preclinical to preregistration stages.
Market forecast features: We forecast drug sales for asymptomatic, intermittent claudication, and critical limb ischemia patient segments through 2027.
Already a Client? Log in to access this report.
Pallavi Malik is a business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Biotechnology, and a Bachelor's degree in Science from the Panjab University, Chandigarh, India. Prior to joining DRG, she has worked as a Senior Business Analyst at the research firm Evalueserve. Her role involved in-depth scientific secondary research, and competitive intelligence across multiple domains (such as oncology, ophthalmology and CVD) including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, competitor benchmarking, and opportunity assessment.
Mike joined Decision Resources as an epidemiologist in 2006. He has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis and systematic reviewing. He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He has also been responsible for developing national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in non-communicable epidemiology. Dr. Hughes received his in risk modeling in intensive care in 2003 from City University, London and is currently enrolled in a program in statistical causation and foundations of probability theory at the University of Nottingham.
Shreya Saxena is a senior business insights analyst in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. She obtained an degree with specializations in Marketing and HR, and a Bachelor's degree in Pharmacy from the GGSIPU University, Delhi, India. Prior to joining DRG, she has worked as a Business Analyst at the research firm Evalueserve. Her role involved in-depth commercial, and scientific secondary research, and competitive intelligence across multiple indications (such as atrial fibrillation, ACS, VTE, heart failure and women’s health), including pipeline analysis, clinical trials assessment, disease landscaping, product and company profiling, and financial assessment and benchmarking.